Two fields, six lines: neuroimaging biomarkers and ultrasound-based therapies.
Multimodal PET/MRI biomarkers for Parkinson's disease and its progression.
We integrate computational modeling and AI for personalized medicine.
HIFU enables precise, incision-free lesioning of deep brain structures.
We build predictive lesion models and decision-support systems, with 400+ cases of experience.
Low-intensity ultrasound + microbubbles transiently open the BBB for targeted delivery.
We focus on quantitative permeability metrics and AI-driven decision tools.
TUS reversibly modulates cortical excitability with high spatial precision.
We use TUS to identify and validate therapeutic targets before definitive interventions.
Explore the projects translating these lines into reality.
View projects →
